Research and Markets: Global Tuberculosis Drugs Market 2011-2015 with Eli Lilly and Co. GlaxoSmithKline plc. Pfizer …

DUBLIN--(BUSINESS WIRE)--

Research and Markets (http://www.researchandmarkets.com/research/l8sxhx/global) has announced the addition of the "Global Tuberculosis Drugs Market 2011-2015" report to their offering.

TechNavio's analysts forecast the Global Tuberculosis Drugs market to grow at a CAGR of 6.75 percent over the period 2011-2015. One of the key factors contributing to this market growth is the increase in the outbreak of TB-HIV co-infections. The Global Tuberculosis Drugs market has also been witnessing the trend of increased focus on TB vaccine development. However, insufficient demand in developed countries could pose a challenge to the growth of this market.

TechNavio's report, the Global Tuberculosis Drugs market 2011-2015, has been prepared based on an in-depth analysis of the market with inputs from industry experts. The report covers the Americas, and the EMEA and APAC regions; it also covers the Global Tuberculosis Drugs market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.

Commenting on the report, an analyst from TechNavio's Healthcare team said: ''Currently, the Bacille Calmette-Guerin (BCG) vaccine is the only vaccine for Tuberculosis (TB). It is inconsistent in protecting against the adolescent or adult form of TB, particularly pulmonary or lung TB. Furthermore, the World Health Organization (WHO) is no longer recommending it for the treatment of TB in HIV-infected infants. A rich pipeline of new vaccines has emerged over the years with almost 15 TB vaccines entering clinical trials. Companies are more focused on developing effective vaccines against the spread of the TB infection. In developing countries, there is an increased focus on improving vaccine production capacity to address needs.''

According to the report, the emergence of multidrug-resistant TB (MDR-TB) and extensive drug-resistant TB (XDR-TB) strains along with increase in the number of other mutant and antibiotic-resistant TB strains is propelling the growth of the Global Tuberculosis Drugs market.

For more information visit http://www.researchandmarkets.com/research/l8sxhx/global

More:
Research and Markets: Global Tuberculosis Drugs Market 2011-2015 with Eli Lilly and Co. GlaxoSmithKline plc. Pfizer ...